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Abstract 
Particle-based delivery systems are a promising approach to enhance antigen-specific 
immunity for use in vaccines. Chitosan, a natural polysaccharide derived from the 
exoskeletons of crustaceans, shows great potential as a vaccine carrier due to its favorable 
properties as a biomaterial, including biocompatibility and biodegradability. In this study, the 
intracellular uptake of chitosan nanoparticles is explored and compared to that of other 
commonly used particle-based delivery vehicles, such as poly (lactic-co-glycolic acid) 
(PLGA). Fluorescein isothiocyanate-labeled bovine serum albumin (FITC-BSA) was used as 
a model protein antigen and encapsulated in both chitosan particles via precipitation-
coacervation and PLGA particles via double emulsion solvent evaporation. Fluorescence 
microscopy images showed that, when co-incubated with dendritic cells, all cells were found 
to internalize FITC-BSA-chitosan nanoparticles. Additionally, punctate fluorescence in the 
cytoplasm indicated that at least some of the particles were within endosomes at early (less 
than 24 hour) time points. Furthermore, flow cytometry results showed chitosan particles to 
have a greater uptake (74%) by dendritic cells compared to PLGA particles (32%) or soluble 
protein (43%) at early time points (1 hour). 
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1. Introduction 
 Vaccines play a vital role in modern medicine. While vaccines have been responsible for 
the near elimination of some major diseases, such as smallpox and poliomyelitis, as well as 
significant control over many other illnesses, there remain several diseases that require new and 
improved vaccine formulations to enhance current treatments [1]. Presently, vaccine 
development studies focus on using subunit antigens to elicit an immune response, which is a 
safer but less effective method than delivering whole pathogens. Subunit antigens are rapidly 
degraded by proteases upon injection. Furthermore, subunit antigens lack the requisite 
immunostimulatory signals required for a robust adaptive immune response [2]. A delivery 
system, therefore, is needed to increase the persistence of antigens and enhance the immune 
response. Particle-based delivery systems in which antigens are encapsulated in polymeric nano- 
or microparticles are a promising approach and under intense investigation. 
 Several advantages of antigen encapsulation by nano- and/or micro particles have been 
established. For one, encapsulation prevents antigen degradation. Two, polymeric particles can 
be engineered to certain specifications, such as amount of adjuvant loading. Finally, antigen-
presenting cells (APC) like macrophages and dendritic cells (DCs) phagocytize and process the 
antigen-containing particles [2]. These properties demonstrate the potential of particle-based 
vaccine delivery systems to enhance antigen-specific immunity. 
 The most commonly used material for particle-based delivery is poly (lactic-co-glycolic 
acid) (PLGA), but another polymer, chitosan, shows great potential as a vaccine carrier. 
Chitosan, a natural polysaccharide derived from the exoskeletons of crustaceans, has recently 
been introduced in several biomedical applications due to its favorable properties and versatility 
as a biomaterial, including biocompatibility and biodegradability. Chitosan is mucoadhesive, 
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which has led to its exploration as a nasal and oral vaccine carrier. In addition, chitosan is highly 
hydrophilic and positively charged, indicating its high protein loading capacity [1, 2]. Thus, this 
remarkable natural polymer has shown great potential as a particle-based vaccine delivery 
system, and may have advantages over PLGA. 
 Previous research in our lab, the Laboratory of Vaccine and Immunotherapy Delivery at 
the University of Arkansas, has demonstrated that chitosan’s properties support its potential as an 
effective vaccine carrier. Chitosan particles efficiently deliver encapsulated antigens and enhance 
the activation of both macrophages and DCs [2]. Furthermore, antigen-encapsulated chitosan 
particles outperformed soluble antigens in eliciting both humoral and cell-mediated antigen-
specific immune responses [2]. 
 To supplement these findings, my research focused on characterizing the uptake of 
chitosan nanoparticle-based vaccines and comparing the uptake to other nanoparticles commonly 
used in particle-based vaccine delivery, such as PLGA. Fluorescence microscopy was used to 
determine the time course of internalization of nanoparticles by DCs. Flow cytometry was then 
used to further quantify uptake. Cytotoxicity became of interest in the study, so cell viability 
assays were performed and PI stain was used with flow cytometry as a measure of cell viability. 
Finally, scanning electron microscopy (SEM) images were taken of both chitosan particles and 
PLGA particles in the interest of comparing their morphologies. Fluorescein isothiocyanate-
labeled bovine serum albumin (FITC-BSA) was used as a model protein antigen and 
encapsulated in both chitosan particles via precipitation-coacervation and PLGA particles via 
double emulsion solvent evaporation.  
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2. Materials and Methods 
2.1 Cell Culture 
 A murine immature dendritic cell line, JAWS II cells, were cultured in complete media 
consisting of DMEM supplemented with 20% FBS, 1% penicillin/streptomycin, 1% L-
glutamine, and 5ng/ml GM-CSF. 
 
2.2 Particle synthesis 
 Chitosan particles encapsulating FITC-BSA were prepared via precipitation-coacervation 
using low molecular weight chitosan [Batch #: MKBD0020, 448869-50G, CAS 9012-76-4]. For 
full protocol, see appendix A. PLGA particles encapsulating FITC-BSA were prepared via 
double emulsion solvent evaporation using PLGA (50/50). For full protocol, see appendix B. 
Particles were lyophilized before further use. Particle size was measured via dynamic light 
scattering (DLS) (Nano ZS90, Malvern Instruments, Malvern, UK). 
 
2.3 Fluorescence Microscopy 
 Phase contrast images and fluorescence images were taken with a Nikon eclipse Ti 
fluorescence microscope. Prior to imaging, cells were seeded in a 6-well plate at 2 million cells 
per well and incubated overnight. Particle suspensions, chitosan or PLGA at 200 µg/ml, or FITC-
BSA solution at 20 µg/ml, were then added to different wells. Cells alone was used as a negative 
control. The plate was incubated for the desired period of time. The samples were washed three 
times with phosphate buffered saline (PBS) prior to imaging. 
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2.4 Flow Cytometry 
 Flow cytometry was used to quantify cell-by-cell uptake of particles or FITC-BSA. 
Briefly, cells were plated 1 million cells per well in a 6-well plate. Chitosan or PLGA suspension 
(200 µg/ml) or FITC-BSA solution (20 µg/ml) were added to appropriate wells. The plate was 
incubated for the desired time, either 1 hour or 24 hours. Samples were harvested after the 
incubation period and were washed and re-suspended in PBS prior to measuring. PI stain (2µl) 
was added just before measuring. 
 
2.5 Viability Assays 
 Two different viability assay kits were used: 1) CytoTox-Glo Cytotoxicity Assay (see 
appendix C for product instructions) and 2) CellTiter-Glo Luminescent Cell Viability Assay (see 
appendix D for product instructions). Briefly, JAWS II cells were seeded in a 96-white wall 
plate. Particle suspensions or FITC-BSA solution was added to appropriate wells and the plate 
was incubated for 1 hour or 24 hours. Plates were prepared for measurement after the incubation 
period according to the respective assay protocol. Luminescence was read with a plate reader and 
reported in relative light units (RLU). 
 
2.6 Scanning Electron Microscopy 
 Lyophilized particles were sputter coated with gold prior to imaging. SEM images were 
acquired at a beam voltage of 10-15 kV. 
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3. Results and Discussion 
 Chitosan particles had a mean diameter size of 521.5nm ± 123.4 (n=18) and PLGA 
particles had a mean diameter of 281.1nm ± 52.3 (n=4) as determined via dynamic light 
scattering (DLS). Fluorescence images verified the successful encapsulation of fluorescein 
isothiocyanate-labeled bovine serum albumin (FITC-BSA) by chitosan nanoparticles (Figure 1).  
!
Figure 1. Chitosan nanoparticles encapsulating FITC-BSA (green). 40x.  
  The time course of internalization of chitosan particles by dendritic cells was 
determined using fluorescence microscopy. When co-incubated with JAWS II cells, all cells 
were found to internalize FITC-BSA-chitosan nanoparticles. Additionally, punctate fluorescence 
in the cytoplasm indicated that at least some of the particles were within endosomes at early (~1 
hour) time points (Figure 2). Cells alone showed no fluorescence, which was expected for the 
negative control. Cells co-incubated with chitosan particles appear to have the highest intensity 
of FITC fluorescence signal. Cells co-incubated with FITC-BSA or with PLGA particles showed 
some fluorescence but less than that of cells with chitosan particles. This suggests that the 
dendritic cells more readily took up chitosan particles than PLGA particles or soluble protein 
antigens. 
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Figure 2. Representative phase contrast images (left) and corresponding fluorescence (green) images (right) 
of cells alone (A) or cells co-incubated with FITC-BSA (B), chitosan particles (C), or PLGA particles (D). 1-
hour incubation period. All images: 40x. Performed 3 times with similar results. 
 To quantify intracellular uptake, cell-by-cell analysis was performed using flow 
cytometry. An increase in intensity, or right shift, in the FITC channel (P3) denotes an increase 
in protein (FITC-BSA) or particle uptake. Likewise, an increase in intensity in the PE channel 
(P2) denotes an increase in percentage of the population stained with propidium iodide (PI). PI 
stain was included as a measure of cell viability. 
 It was found that intracellular uptake is greater with chitosan particles than PLGA 
particles or FITC-BSA (Figure 3). After a 1-hour incubation period, cellular uptake of chitosan 
was 74% compared to only 32% with PLGA and 43% with FITC-BSA. Uptake showed an 
increase at 24 hours compared to 1 hour with both particles and FITC-BSA, but chitosan 
particles retained the highest value, 77%, compared to 45% with PLGA and 59% with FITC-
BSA. These results, together with fluorescence microscopy images, support that chitosan 
particles stimulate greater intracellular uptake than PLGA particles or soluble protein antigens. 
 The PE channel showed that cell viability appears to decrease more with chitosan 
particles than PLGA particles after 24-hour incubation. At 1 hour, there was little decrease in cell 
A 
B 
C 
D 
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viability with either particle. At 24 hours, however, cell viability had decreased by 31% with 
chitosan particles and only 11% with PLGA particles. There were a few things to consider when 
analyzing this result. First, since uptake of chitosan particles was significantly higher than that of 
PLGA, the larger decrease in cell viability with chitosan particles may be due to a higher 
concentration (dose) of particles rather than increased cytotoxicity. It is also important to note 
that while the percentage values provide a good quantitative measure of the increase in signal 
intensity, the visual shift in intensity provides the best comparison. In other words, it is difficult 
to affirm that, for example, there was precisely a 31% decrease in cell viability at 24 hours of 
cells co-incubated with chitosan particles. With this in mind, the shifts in the PE channel of cells 
co-incubated with chitosan particles or PLGA particles at 24 hours are visually more similar than 
the percentages suggest. The shift in the FITC channel, on the other hand, is obviously more 
dramatic with chitosan particle uptake compared to PLGA particle uptake. Additionally, there 
may be some interaction between chitosan and PI causing the shift in intensity. Repeat studies 
are necessary to verify that PI and chitosan are not interacting. 
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%
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Figure 3. Flow cytometry of cells alone (A), cells co-incubated with FITC-BSA for 1 hour (B) or 24 hours (C), 
cells co-incubated with chitosan particles for 1 hour (D) or 24 hours (E), and cells co-incubated with PLGA 
particles for 1 hour (F) or 24 hours (G). P1 (left) is the selected population, P2 (middle) is a PE channel gate, and 
P3 (right) is a FITC channel gate. The percentage in the top right corner of each image is the percent of the parent 
population that corresponds to the selected region or positive channel signal. Performed 3 times (only once with PI 
stain) with similar results. 
93.9% 2.4% 74.3% 
51.8% 31.4% 77.8% 
D 
E 
93.7% 2.4% 32.4% 
F 
82.2% 10.8% 45.1% 
G 
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 Viability assays were used to further investigate cytotoxicity of both polymeric particles. 
Results with the CytoTox-Glo Cytotoxicity Assay showed that there was no significant decrease 
in cell viability after 1 hour of incubation with either chitosan particles (P=0.158) or PLGA 
particles (P=0.347) (Figure 4). After 24 hours of incubation, however, there was a significant 
decrease in cell viability in cells co-incubated with PLGA particles (P=0.0047). There was not a 
significant decrease in cell viability in cells co-incubated with chitosan particles (P=0.129) 
(Figure 5). 
 Results with the CellTiter-Glo Luminescent Cell Viability Assay showed that as particle 
concentration increases, viable cell luminescence decreases. There was a significant decrease in 
cell viability with 25µg and 50µg of PLGA particles and with 50µg of chitosan particles (Figure 
6). Table 1 shows the measured RLU values and Figure 7 shows the percent difference 
calculations of cell viability as particle concentration increases between cells alone and cells co-
incubated with chitosan particles or between cells alone and cells co-incubated with PLGA 
particles. 
 It appears that chitosan particles are less toxic than PLGA particles. It is noteworthy, 
however, that particle concentrations in this study are relatively low, so results may vary at 
higher concentrations. Also, results could not yet be reproduced, so further experimentation is 
necessary to validate these results or draw more concrete conclusions. 
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Figure 4. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with chitosan particles or 
PLGA particles for 1 hour. Particle concentration was 200µg/ml. Bars indicate relative light units (RLU) as 
determined by CytoTox-Glo Cytotoxicity Assay. (n=1) 
!
Figure 5. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with chitosan particles or 
PLGA particles for 24 hours. Particle concentration was 200µg/ml. Bars indicate relative light units (RLU) as 
determined by CytoTox-Glo Cytotoxicity Assay. *p<0.05 compared to cells alone. (n=1) 
!
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Table 1. Viable cell luminescence measured in relative light units (RLU) as determined by CellTiter-Glo 
Luminescent Cell Viability Assay. Values were used in Figures 6 and 7. 
 
 
!
Figure 6. Viable cell luminescence. JAWS II cells were incubated alone or co-incubated with either chitosan 
particles or PLGA particles for 24 hours at increasing concentrations. Bars indicate relative light units (RLU) as 
determined by CellTiter-Glo Luminescent Cell Viability Assay. *p<0.05 compared to cells alone. **p<0.01 
compared to cells alone. Samples were plated in triplicate, so error bars represent standard deviation of three wells 
of repeated samples in the same study. (n=1) 
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Figure 7. Percent difference in cell viability in cells co-incubated with chitosan particles or PLGA particles 
compared to cells alone at increasing amounts of particles. Calculated using values from Table 1. 
 Lastly, I investigated the morphology of chitosan particles and PLGA particles with 
scanning electron microscopy (SEM). Representative SEM images are shown in Figure 6. The 
images I acquired with PLGA did not match those found in literature, so I cannot be sure that the 
chitosan images are accurate either. It may be that a different sample preparation method is 
required to obtain better images. 
 
!
Figure 8. Representative SEM images of chitosan particles (A) and PLGA particles (B). 
A B 
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 There are several avenues of future research that could be pursued. For one, repeat 
studies using the CellTiter-Glo Luminescent Cell Viability Assay kit need to be performed in 
order to draw conclusions about the differences in cytotoxicity between chitosan particles and 
PLGA particles. Moreover, repeat studies using PI stain with flow cytometry could be used to 
support the viability assay results. It would be worthwhile to experiment with a higher and wider 
range of particle concentrations, as well. 
 Furthermore, multiphoton microscopy would provide better, clearer images than the 
fluorescence microscopy used in this study. Multiphoton images would show greater detail and 
more qualitative information could probably be determined by analyzing the intracellular uptake 
of particles more closely. 
 Additionally, performing flow cytometry with samples incubated for periods greater than 
24 hours may be useful in determining intracellular retention rate of particles. This data could 
indicate the time period between uptake by DCs and DC maturation and antigen presentation. 
 Another study to pursue is SEM imaging. Morphology of the particles may play a role in 
their intracellular behavior, so knowledge of the differences in morphology between chitosan and 
PLGA particles may be valuable in analyzing the differences in the cellular mechanisms of 
uptake and processing of either particle. 
 
4. Conclusions 
 In conclusion, dendritic cells internalized FITC-BSA-encapsulated chitosan nanoparticles 
at early (~1 hour) time points. When co-incubated with JAWSII cells, all cells were found to 
internalize FITC-BSA-chitosan nanoparticles. Punctate fluorescence in the cytoplasm indicated 
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that at least some of the particles were within endosomes at early (less than 24 hour) time points. 
 Cellular uptake of particles appears to be greater with chitosan particles compared to 
PLGA particles at early time points (1 hour). Intracellular uptake increased from 1 hour to 24 
hours with both chitosan and PLGA particles, but chitosan particle uptake remained significantly 
higher (77% compared to 45% with PLGA). 
 Additional data is required, but there may be a significant difference in cytotoxicity 
between PLGA and chitosan particles. My results show that chitosan particles are somewhat less 
toxic than PLGA particles after 24-hour incubation with cells. 
 Tunable release kinetics is a key advantage of polymeric nanoparticle delivery systems. 
The increased uptake with chitosan particles compared to PLGA particles suggest chitosan 
particles may provide greater sustained release of loaded molecules, and therefore could present 
the greatest immunostimulatory response. 
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Appendix A 
Protocol: Chitosan Nanoparticles 
(Bhanu, Wilson et al 2013) 
1. Prepare 2% v/v acetic acid solution by adding 200 µl acetic acid in 9.8 ml of DI water 
2. Add 10 mg chitosan (Sigma Low MW) to the acetic acid solution on a magnetic stirrer and 
mix for 1 hour (~850 RPM). 
3. Add 100 µl  (or 1 mg) of FITC-BSA and mix for 10 min in the dark (~800 RPM) 
4. Prepare 10% w/v sodium sulfate solution by adding 1 g sodium sulfate to 10 ml DI water and 
mix 
5. Use infusion pump to add 1 ml sodium sulfate solution to chitosan solution drop wise until 
particle formation is observed 
6. Add 50 mg Pluronic F-68 to the solution and stir for 5 min 
7. Stir the nanoparticle solution for another 30 minutes while sonicating (30-40 W) every 15 min 
for 60 sec to obtain better dispersion 
8. Use the nanosizer to determine the size of the chitosan nanoparticles 
• 1 ml DI water + 100 µl chitosan solution in cuvette 
• Remove any bubbles before measuring 
9. Centrifuge at 15000 RPM for 8 min 
10. Keep supernatant (wrap in foil and store in 4°C fridge to use in drug loading efficiency 
calculations) and resuspend the pellet in ~10 ml DI water and sonicate for 1 min in water 
bath sonicator 
11.  Centrifuge again at 15000 RPM for 8 min 
12. Dispose of the supernatant and resuspend the pellet in 5 ml of DI water 
13. Transfer the solution to a 15 ml conical tube, wrap in foil, and store in -80°C freezer 
Appendix B 
Protocol: PLGA nanoparticles (300nm) 
(Bhanu et al, 07/14/13) 
PLGA nanoparticles encapsulating OVA antigen were prepared using a double emulsion solvent 
evaporation method. 
Note: Make sure all the components used in the reactions including beakers, pipettes etc. are of 
glass. Do not use plastic containers or pipettes to handle the solutions. 
1. Prepare 12ml 2% w/v PLA solution by taing 240mg of PVA into 12ml DI water 
2. Mix the solution at room temperature for 1 hour 
3. Prepare protein solution by dissolving 2 mg of FITC-BSA in 200µl DI water (use black 
eppindorf tube to protect from light) 
4. Prepare 3% PLGA solution by dissolving 90mg of PLGA (50/50) in 3ml of 
dichloromethane (DCM) in a 10ml beaker 
5. Cover the beaker mouth tightly with aluminum foil 
6. Mix the solution at 600 RPM for 10 – 15 minutes 
7. After 15 minutes, increase the stirring speed of PLGA mixture to 800 RPM and slowly 
add the protein solution drop wise 
8. Transfer the mixture to an ice bath and sonicate at 40W for 30 seconds 
9. Keep the PVA solution on the stirrer mixing at 800 RPM 
10. Slowly add the PLGA mixture to PVA solution using a glass transfer pipette 
11. Let the solution mix for 2 minutes 
12. Transfer the beaker to an ice bath and sonicate the solution at 50W for 2 minutes 
13. Transfer the beaker back to stirrer 
14. Close the mouth of the beaker with aluminum foil 
Appendix B 
15. Poke 3-4 holes in the aluminum foil lid using a pipette tip 
16. Leave the beaker on stirrer overnight to allow DCM to evaporate 
17. After stirring overnight, transfer PLGA nanoparticles solution into centrifuge tubes 
18. Weigh balance the centrifuge tube and centrifuge for 10 minutes at 20,000 RPM using 
high speed centrifuge 
19. Collect the supernatant – Can be used to determine the loading efficiency 
20. Re-suspend the pellet in 10ml DI water – Make sure the particles are mixed well into the 
solution 
21. Centrifuge the particle solution for 10 minutes at 20,000 RPM using high speed 
centrifuge 
22. Discard the supernatant and re-suspend the protein loaded PLGA nanoparticles in 10ml 
DI water 
23. Mix well and freeze at -80°C before freeze drying 
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1. Description
The CytoTox-Glo™ Cytotoxicity Assay(a,b) is a single-reagent-addition,
homogeneous, luminescent assay that allows measurement of the number of
dead cells in cell populations (Figure 1). The CytoTox-Glo™ Assay shows
excellent correlation with other methods of assessing cell viability (Figure 2).
The CytoTox-Glo™ Assay measures a distinct protease activity associated with
cytotoxicity (1). The assay uses a luminogenic peptide substrate (alanyl-alanyl-
phenylalanyl-aminoluciferin; AAF-Glo™ Substrate) to measure “dead-cell
protease activity”, which is released from cells that have lost membrane integrity
(Figure 3). The AAF-Glo™ Substrate cannot cross the intact membrane of live
cells and does not generate any appreciable signal from the live-cell population.
The assay selectively detects dead cells (Figure 4). The CytoTox-Glo™ Assay
relies on the properties of a proprietary thermostable luciferase (Ultra-Glo™
Recombinant Luciferase), which uses aminoluciferin as a substrate to generate a
stable "glow-type" luminescent signal and is formulated to improve
performance across a wide range of assay conditions.
With the addition of Lysis Reagent (provided), the CytoTox-Glo™ Cytotoxicity
Assay also can deliver the luminescent signal associated with the total number
of cells in each assay well. Viability can be calculated by subtracting the
luminescent signal resulting from experimental cell death from total
luminescent values (Section 5).
CytoTox-Glo™ Cytotoxicity Assay
All technical literature is available on the Internet at: www.promega.com/protocols/ 
Please visit the web site to verify that you are using the most current version of this
Technical Bulletin. Please contact Promega Technical Services if you have questions on use
of this system. E-mail: techserv@promega.com
Promega Corporation · 2800 Woods Hollow Road · Madison, WI 53711-5399 USA 
Toll Free in USA 800-356-9526 · Phone 608-274-4330 · Fax 608-277-2516 · www.promega.com
Part# TB359 Printed in USA.
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Step 2. Measure total cytotoxicity (optional).
Total Cell Number – Dead-Cell Number = Viable Cell Number  
Figure 1. Schematic diagram of the CytoTox-Glo™ Cytotoxicity Assay.
Assay Advantages
Measure the Relative Number of Dead Cells in Culture: Measure cytotoxicity
by adding a single reagent with the homogeneous “add-mix-measure” protocol.
Normalize Data for Cytotoxicity: Data normalization for dead-cell number
makes results more comparable well-to-well, plate-to-plate and day-to-day.
Measure the Relative Number of Remaining Viable Cells Using a Total Lysis
Protocol: Correlate increased cytotoxicity with a reduction in viable cells.
Improve Your Data: Reduce statistical probability of false positives (or negatives),
and eliminate fluorescence interference issues with a stable luminescence readout.
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Figure 2. The CytoTox-Glo™ Cytotoxicity Assay shows strong correlation with
established methods for measuring cytotoxicity. Panel A. The CytoTox-Glo™
Cytotoxicity Assay signal from serial twofold dilutions of dead cells plotted against
results from the CytoTox-ONE™ Homogeneous Membrane Integrity Assay, which
measures LDH release. Panel B. The CytoTox-Glo™ Assay signal from serial
dilutions of dead cells plotted against results achieved using ethidium homodimer
(DNA quantitation).
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Figure 3. Cleavage of the luminogenic AAF-Glo™ Substrate by dead-cell protease
activity. Following cleavage, a substrate for luciferase (aminoluciferin) is released,
resulting in the luciferase-mediated production of light.
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Figure 4. The CytoTox-Glo™ Cytotoxicity Assay signal derived from lysed cells
is extremely sensitive and proportional to cell number and demonstrates selective
detection of dead cells.
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2. Product Components and Storage Conditions
Product Size Cat.#
CytoTox-Glo™ Cytotoxicity Assay 10ml G9290
G9290 contains sufficient reagents for 100 assays at 100µl per assay in a 96-well plate
format or 400 assays at 25µl per assay in a 384-well plate format. Includes:
• 1 bottle AAF-Glo™ Substrate
• 2 × 5ml Assay Buffer
• 1 × 40µl Digitonin
Product Size Cat.#
CytoTox-Glo™ Cytotoxicity Assay 5 × 10ml G9291
G9291 contains sufficient reagents for 500 assays at 100µl per assay in a 96-well plate
format or 2,000 assays at 25µl per well in a 384-well format. Includes:
• 5 bottles AAF-Glo™ Substrate
• 10 × 5ml Assay Buffer
• 1 × 175µl Digitonin
Product Size Cat.#
CytoTox-Glo™ Cytotoxicity Assay 2 × 50ml G9292
G9292 contains sufficient reagents for 1,000 assays at 100µl per assay in a 96-well plate
format or 4,000 assays at 25µl per well in a 384-well format. Includes:
• 2 bottles AAF-Glo™ Substrate
• 4 × 25ml Assay Buffer
• 2 × 175µl Digitonin
Storage Conditions: Store the CytoTox-Glo™ Cytotoxicity Assay components
at –20°C, protected from light. See product label for expiration date information.
3. Reagent Preparation and Storage
1. Thaw the CytoTox-Glo™ Cytotoxicity Assay components in a 37°C water bath.
Mix the components to ensure homogeneity.
2. Prepare the CytoTox-Glo™ Cytotoxicity Assay Reagent by transferring the
contents of one bottle of Assay Buffer to the AAF-Glo™ Substrate bottle.
Note: The appearance of the AAF-Glo™ Substrate prior to addition of Assay
Buffer may vary from lot to lot. This variation does not affect assay
performance.
3. Prepare the Lysis Reagent one of two ways, depending on the protocol used.
a. For Section 4.A, transfer Assay Buffer (2.75ml for Cat.# G9290 and
G9291; 13.75ml for Cat. G9292) to a conical tube. Prepare Lysis Reagent
by transferring Digitonin (13µl for Cat.# G9290 and G9291; 65µl for Cat.
G9292) to the conical tube containing Assay Buffer. Mix to ensure
homogeneity.
b. For Sections 4.B and 4.C, transfer Digitonin (33µl for Cat.# G9290 and
G9291; 162µl for Cat.# G9292) to the Assay Buffer (5ml for Cat.# G9290
and G9291; 25ml for Cat.# G9292). Mix well to ensure homogeneity.
Note: Because the Lysis Reagent can be added before or after the
CytoTox-Glo Cytotoxicity Assay Reagent, the volume of digitonin added
to Assay Buffer differs. The difference in the volume of cells means that
the volume of digitonin has to be adjusted to be delivered at the same
lytic concentration.
Storage: For optimal results, use freshly prepared CytoTox-Glo™ Cytotoxicity
Assay Reagent (rehydrated AAF-Glo™ Substrate). Use within 12 hours if stored
at room temperature. The CytoTox-Glo™ Cytotoxicity Assay Reagent and Lysis
Reagent can be stored at 4°C for up to 7 days with no appreciable loss of
performance. The CytoTox-Glo™ Cytotoxicity Assay Reagent may be stored in
single-use aliquots for up to 4 months at –70°C. Freezing and thawing will
damage the reagent and must be avoided.
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4. Protocols
Materials to be Supplied by the User
• 96-, 384- or 1536-well, white-walled tissue culture plates compatible with
luminometer and fluorometer (clear or solid bottom)
• multichannel pipettor or liquid-dispensing robot
• reagent reservoirs
• luminescence plate reader or multimode reader
• orbital plate shaker
• positive control cytotoxic compound
If you have not performed this assay with your cell line previously, we strongly
recommend that you determine the assay sensitivity for your cells using one of
the two methods described below (Section 4.A or 4.B). Use Method 1 to
determine the linear range of the assay for your cell type. Use Method 2 to
determine the practical sensitivity once you have already chosen the number of
cells to use in the assay. If you do not need to determine assay sensitivity for
your cells, proceed to Section 4.C.
4.A. Determining Assay Sensitivity, Method 1
In this method, the Lysis Reagent is added as the first reagent to simulate
experimental cytotoxicity. Lysis Reagent is added as the first reagent to effect
100% cytotoxicity in the presence of a limited number of cells to determine
assay sensitivity. The luminescence measured reflects total cell luminescence.
In all other assay applications, Lysis Reagent is added after the CytoTox-Glo™
Reagent. CytoTox-Glo™ Reagent is first added, and luminescence is measured
to determine dead cell luminescence. Lysis Reagent is then added, and
luminescence is measured to determine total cell luminescence. The final
concentration of the Lysis Reagent used in this method is different than that
when Lysis Reagent is added after the CytoTox-Glo™ Reagent. These two
concentrations of Lysis Reagent cannot be used interchangeably.
1. Harvest adherent cells (by trypsinization, etc.), wash with fresh medium to
remove residual trypsin and resuspend in fresh medium.
Note: For cells growing in suspension, proceed to Step 2.
2. Determine the number of viable cells by trypan blue exclusion using a
hemacytometer, and then dilute to 100,000 viable cells/ml in at least 3.0ml
of fresh medium.
Note: Concentrate cells by centrifugation if the cell suspension is less dense
than 100,000 cells/ml.
3. Add 100µl of the 100,000 cell/ml suspension (10,000 cells/well) to all wells
of row A and B in a 96-well plate.
4. Add 100µl of fresh medium to all wells in rows B–H.
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4.A. Determining Assay Sensitivity, Method 1 (continued)
5. Using a multichannel pipettor, mix the cell suspension in row B by
pipetting, being careful not to create foam or bubbles. Transfer 100µl from
each well of row B to row C. Repeat mixing, and transfer 100µl from row C
to row D. Continue this process to row G. After mixing the diluted
suspension in row G, aspirate 100µl from the wells, and discard. This
procedure creates dilutions of 10,000 cells/well in row A to 156 cells/well
in row G. Row H will serve as the no-cell background control (Table 1).
6. Prepare Lysis Reagent according to instructions in Section 3, Step 3.a.
7. Using a multichannel pipettor, add 50µl of Lysis Reagent to all wells of
columns 7–12 to lyse cells; these are the treated samples. Add 50µl of the
remaining Assay Buffer to all wells in columns 1–6 so that all wells have
equal volumes; these are the untreated samples. Mix by orbital shaking at
700–900rpm for at least 1 minute.
8. Prepare the CytoTox-Glo™ Cytotoxicity Assay Reagent as described in
Section 3, and add 50µl to each well. Mix briefly by orbital shaking, and
incubate at room temperature for 15 minutes.
Note: Maximal sensitivity is achieved within 15 minutes. The signal intensity
will remain largely unchanged for approximately 30 minutes to 1 hour,
depending on plate-well density. The signal half-life is approximately
5 hours in a 96-well plate but shorter (about 2 hours) in a 1536-well plate.
9. Measure luminescence.
Note: You may need to adjust instrument gain setting (applied
photomultiplier tube energy).
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Table 1. Schematic Diagram of 96-Well Plate Layout.
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10. Calculate the signal-to-noise (S:N) ratios to determine practical sensitivity for
your cell type for each dilution of cells (10,000 cells/well; 5,000 cells/well, etc.).
Cytotoxicity S:N = (Average Treated RLU – Average Untreated RLU)S.D. of No-cell Background Controls (H1 through H6)
Note: The practical level of assay sensitivity for either assay is a signal-to-
noise ratio of greater than 3 standard deviations (derived from reference 2).
4.B. Determining Assay Sensitivity, Method 2
1. Harvest adherent cells (by trypsinization, etc.), wash with fresh medium to
remove residual trypsin and resuspend in fresh medium.
Note: For cells growing in suspension, proceed to Step 2.
2. Determine the number of viable cells by trypan blue exclusion using a
hemacytometer, then dilute to 100,000 viable cells/ml in at least 20ml of
fresh medium.
Note: Concentrate the cells by centrifugation if the cell suspension is less
dense than 100,000 cells/ml.
3. Divide the volume of diluted cells into two separate tubes. Subject one tube
to “moderate” sonication, which is empirically determined by post-sonication
morphological examination, to disrupt cell membrane integrity and to
simulate a 100% population of dead cells. The second tube of untreated
cells will serve as the maximum viable population.
4. Create a spectrum of viability by blending sonicated and untreated
populations in 1.5ml tubes as described in Table 2.
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Table 2. Spectrum of Viability Generated by Blending Sonicated and
Untreated Cells.
Percent Viability Volume of SonicatedCells (µl)
Volume of Untreated
cells (µl)
100 0 1,000
95 50 950
90 100 900
75 250 750
50 500 500
25 750 250
10 900 100
5 950 50
0 1,000 0
4.B. Determining Assay Sensitivity, Method 2 (continued)
5. After mixing each blend of sonicated and untreated cells by gentle
vortexing, pipet 100µl of each blend into eight replicate wells of a 96-well
plate. Add the 100% viable cell sample to column 1, 95% viable to column 2,
etc. Add 100µl of cell culture medium only to column 10 to serve as the 
no-cell background control.
6. Add 50µl of CytoTox-Glo™ Cytotoxicity Assay Reagent to all wells, mix
briefly by orbital shaking and then incubate for 15 minutes at room
temperature.
Note: Maximal sensitivity is achieved within 15 minutes. The signal intensity
will remain largely unchanged for approximately 30 minutes to 1 hour,
depending on plate-well density. The signal half-life is approximately
5 hours in a 96-well plate but shorter (about 2 hours) in a 1536-well plate.
7. Measure luminescence.
Total Cell Number (optional)
8. Add 50µl of Lysis Reagent prepared according to instructions in Section 3,
Step 3.b. Mix by orbital shaking, and then incubate at room temperature for
15 minutes.
9. Measure luminescence.
10. Calculate the signal-to-noise (S:N) ratios to determine practical sensitivity
for your cell type for each blend of cell viability (X = 95%, 90%, etc.).
Note: The practical level of assay sensitivity for either assay is a signal-to-
noise ratio of greater than 3 standard deviations (derived from reference 2).
4.C. Example Cytotoxicity Assay Protocol and Viability (by Lysis) Assay Protocol
Representative data are shown in Figure 5.
1. Set up 96-well assay plates containing cells in culture medium at the
desired density.
2. Add test compounds and vehicle controls to appropriate wells so that the
final volume is 100µl in each well (25µl for a 384-well plate).
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Viability S:N =
Average total
luminescence for X% –
Average luminescence
for 0% viable cells
S.D. of 0% viable cell sample
Cytotoxicity S:N =
Average luminescence
for X% –
Average luminescence
for 100% viable cells
S.D. of 100% viable cells
3. Culture cells for the desired test exposure period.
Note: All enzymatic markers for cytotoxicity have finite activity half-lives
(Figure 6). Although the protease marker(s) measured in this assay
demonstrate an improved stability profile compared to other enzymatic
markers under most circumstances, we recommend exposing the cells to
the test compound for 24 hours or less to ensure that cytotoxicity is not
underestimated. If longer exposures are desired, reducing the initial
compound concentration may influence the kinetics of cytotoxicity and
benefit the assessment of cell death.
4. Add 50µl of CytoTox-Glo™ Cytotoxicity Assay Reagent to all wells 
(12.5µl for a 384-well plate). Mix briefly by orbital shaking, and incubate for
15 minutes at room temperature.
Note: Maximal sensitivity will be achieved within 15 minutes. The signal
intensity will remain largely unchanged for approximately 1 hour. The
signal half-life is approximately 5 hours.
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Figure 5. Determining cytotoxicity and viability by lysis. Calcium ionophore was
serially diluted twofold from 100µM in RPMI 1640 medium with 10% FBS in 50µl
volumes. Jurkat cells were added at 10,000 cells/well in a 50µl volume. The plate
was shaken briefly using an orbital shaker and then incubated for 6 hours at 37°C in
5% CO2. The CytoTox-Glo™ Cytotoxicity Assay Reagent was prepared, and 50µl was
added to each well. After another brief mix, the plate was incubated at room
temperature for 15 minutes and the dead cell signal measured using a BMG
POLARStar luminometer. The Lysis Reagent was prepared, and 50µl was added to
each well to achieve complete cell lysis. Luminescence was measured after
15 minutes of incubation at room temperature. The luminescent signal collected
after lysis was adjusted to reflect the “live cell” contribution by subtracting the
initial dead cell signal. The data above are plotted as “dead cell” or “live cell” signal
versus the concentration of calcium ionophore.
4.C. Example Cytotoxicity Assay Protocol and Viability (by Lysis) Assay Protocol 
(continued)
5. Measure luminescence.
6. Add 50µl of Lysis Reagent (prepared according to instructions in Section 3,
Step 3.b) to all wells (12.5µl for a 384-well plate). Mix, and incubate at room
temperature for 15 minutes.
7. Measure luminescence.
8. Calculate the luminescent contribution of previously viable cells (after
lysis) by subtracting the luminescent signal resulting from experimental
cell death (Step 5) from total luminescence death (Step 7).
Viable cell luminescence = Total luminescence – Experimental dead cell 
luminescence
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Figure 6. Half-life of enzymatic markers for cytotoxicity. Jurkat cells were plated 
in white-walled plates in 100µl at a density of 10,000 cells per well in RPMI 1640
medium + 10%FBS. Digitonin was added to appropriate replicate wells in 10µl
(30µg/ml final concentration) every hour for 10 hours to facilitate maximal
cytotoxicity. The plate was incubated at 37°C during this period. CytoTox-Glo™
Reagent and reagents to measure glyceraldehyde-3-phosphate dehydrogenase and
adenylate kinase activities were prepared and added as directed by the manufacturer.
Luminescence was measured after 15 minutes using a BMG POLARstar luminometer.
CytoTox-ONE™ Reagent was prepared and added as directed. Fluorescence was
measured using a Labsystems Fluoroskan Ascent plate reader. All data were
background-subtracted and plotted as a percentage of the last lysis time point.
4.D. Recommended Controls
No-Cell Background Control: Prepare triplicate wells without cells to serve as
the negative control to determine background signal.
Untreated Cells Control: Prepare triplicate wells with untreated cells to serve
as a vehicle control. Add the same solvent used to deliver the test compounds
to the untreated-cells control wells.
Test Compound Control: Prepare triplicate wells without cells and containing
the vehicle and test compound to test for possible interference with the
CytoTox-Glo™ Assay chemistry.
Positive Control for Cytotoxicity: Prepare triplicate wells containing cells
treated with a compound known to be toxic to the cells used in your model
system (staurosporine, ionomycin, etc.).
5. General Considerations
Assay Principle
The CytoTox-Glo™ Assay detects both the dead and live cell populations found
in a sample using sequential luminescent measures. Data are collected as
relative light units (RLU). The CytoTox-Glo™ Assay achieves a signal steady-
state between the dead-cell protease and firefly luciferase from 2,500 dead cells
after about 15 minutes. The same number of live cells in the control well
contribute a small, but measurable, background signal. After addition of
digitonin to lyse remaining viable cells, a new steady-state signal is reached
that represents a proportional increase in the number of dead cells (5,000 total)
in the sample well (Figure 7). Therefore, cells that were initially viable
contribute to the dead cell values after lysis. Because pre- and postlysis signals
are stable after reaching steady-state, the viable cell contribution of any sample
can be determined by a subtractive method:
Signal from Viable Cells = Total Cytotoxicity Signal – Initial Cytotoxic Signal
The Lysis Reagent has the same lytic efficiency as sonication.
Background Luminescence and Inherent Serum Activity
Tissue culture medium supplemented with animal serum may contain detectable
levels of the protease marker used for dead-cell measurement. The level of this
protease activity can vary between different lots of serum. To correct for
variability, background luminescence should be determined using samples that
contain medium plus serum without cells (i.e., the no-cell background control).
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5. General Considerations (continued)
Assay Controls
In addition to a no-cell background control to establish background
luminescence, we recommend including an untreated-cell control to measure
maximum viability and a positive control to measure maximum cytotoxicity in
the experimental design. The maximum viability control is established by adding
the vehicle used to deliver the test compound to test wells. In most cases, this
consists of a buffer system or medium and the equivalent amount of solvent
used to deliver the test compound. Maximum cytotoxicity can be determined
using the Lysis Reagent. See Section 4.A.
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Figure 7. CytoTox-Glo™ Assay principle. Jurkat cells were washed and adjusted to
50,000 cells/ml in fresh RPMI 1640 medium + 10% FBS. The pool was split: One
fraction was treated by mild sonication to cause cell death; the other was untreated.
Equal volumes of treated and untreated cells were added to the same replicate wells
(100µl final volume, 5,000 cell equivalents/well) to represent a sample population
with 50% viable and 50% dead cells. Viability control wells received 50µl containing
2,500 untreated cells and 50µl of RPMI 1640 + 10% FBS. The AAF-Glo™ reagent was
delivered to sample and control wells at 50µl per well. Luminescence was measured
on a BMG POLARstar luminometer in kinetic mode for 25 minutes to collect the
signal from the control and 50% dead populations. The plate was removed, and
Lysis Reagent was added. After mixing by orbital shaking at 700rpm for 1 minute,
luminescence from the total cytotoxicity was measured in kinetic mode for an
additional 25 minutes.
Temperature
The generation of luminogenic product is proportional to the protease activity
of the marker associated with cytotoxicity. The activity of this protease is
influenced by temperature. For best results, we recommend incubating reactions
at a constant temperature to ensure uniformity across the plate. After adding
the CytoTox-Glo™ Cytotoxicity Assay Reagent and mixing briefly, we suggest
one of two methods:
1. Incubate at room temperature in a water-jacketed incubation module
(Me'Cour, etc.).
2. Incubate at room temperature with or without orbital shaking.
Instrumentation
Luminescence mode: Luminescence chemistry does not require an external
light source to generate photons but generally collects unrestricted/unfiltered
light output.
Cytotoxicity Marker Half-Life
The activity of the protease marker released from dead cells has a half-life
estimated to be greater than 10 hours (Figure 6). In situations where cytotoxicity
occurs rapidly such as necrosis and the incubation time is greater than 24 hours,
the degree of cytotoxicity may be underestimated. When using extended
incubation times, adding a lytic detergent such as digitonin may be useful to
determine the total cytotoxicity marker activity remaining (from remaining live
cells).
Luminescent Signal Half-Life
The CytoTox Glo™ Assay chemistry uses a thermostable, recombinant luciferase
to generate a “glow-type” luminescent signal that is proportional to the number
of dead cells in the sample. After a short signal ramping period (0–15 minutes),
the signal reaches a plateau and is relatively stable for a period of approximately
1 hour (Figure 8). Although the signal half-life is greater than 5 hours, we suggest
measuring the luminescent signal at steady-state (15 minutes to 1 hour).
Light Sensitivity
Although the AAF-Glo™ Substrate demonstrates good general photostability,
aminoluciferin can degrade with prolonged exposure to ambient light sources.
We recommend shielding the plates from ambient light at all times.
Cell Culture Medium
The AAF-Glo™ Substrate is introduced into the test well using an optimized
buffer system that mitigates differences in pH from treatment with your test
compound. In addition, the buffer system supports protease activity in a host of
different culture media with varying osmolarities. With the exception of
medium formulations with very high serum content or phenol red indicator, no
substantial performance differences should be observed among media.
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Figure 8. CytoTox-Glo™ Assay signal.
7. Related Products
Cell Viability and Cytotoxicity Assays
Product Size Cat.#
MultiTox-Glo Multiplex Cytotoxicity Assay 10ml G9270
CytoTox-Fluor™ Cytotoxicity Assay 10ml G9260
MultiTox-Fluor Multiplex Cytotoxicity Assay 10ml G9200
CellTiter-Glo® Luminescent Cell Viability Assay 10ml G7570
CellTiter-Fluor™ Viability Assay 10ml G6080
CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay 1,000–4,000 assays G7891
CellTiter-Blue® Cell Viability Assay 20ml G8080
Additional Sizes Available. 
Apoptosis Assays
Product Size Cat.#
Apo-ONE® Homogeneous Caspase-3/7 Assay 10ml G7790
Caspase-Glo® 3/7 Assay 10ml G8091
Caspase-Glo® 8 Assay 10ml G8201
Caspase-Glo® 9 Assay 10ml G8211
Additional Sizes Available. 
Reporter Gene Assays
Product Size Cat.#
Bright-Glo™ Luciferase Assay System 10ml E2610
Steady-Glo® Luciferase Assay System 10ml E2510
Additional Sizes Available. 
Protease Assays
Product Size Cat.#
Calpain-Glo™ Protease Assay 10ml G8501
DPPIV-Glo™ Protease Assay 10ml G8350
Proteasome-Glo™ Chymotrypsin-Like Cell-Based Assay 10ml G8660
Proteasome-Glo™ Trypsin-Like Cell-Based Assay 10ml G8760
Proteasome-Glo™ Caspase-Like Cell-Based Assay 10ml G8860
Proteasome-Glo™ 3-Substrate Cell-Based Assay 10ml G1180
Proteasome-Glo™ 3-Substrate System 10ml G8531
Proteasome-Glo™ Caspase-Like Assay 10ml G8641
Proteasome-Glo™ Chymotrypsin-Like Assay 10ml G8621
Proteasome-Glo™ Trypsin-Like Assay 10ml G8631
Additional Sizes Available.
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7. Related Products (continued)
cAMP Assay
Product Size Cat.#
cAMP-Glo™ Assay 300 assays V1501
Additional Sizes Available.
ADME Assays
Product Size Cat.#
P450-Glo™ CYP1A1 Assay 50ml V8752
P450-Glo™ CYP1B1 Assay 50ml V8762
P450-Glo™ CYP1A2 Assay 50ml V8772
P450-Glo™ CYP2C8 Assay 50ml V8782
P450-Glo™ CYP2C9 Assay 50ml V8792
P450-Glo™ CYP3A4 Assay 50ml V8802
P450-Glo™ CYP3A7 Assay 50ml V8812
P450-Glo™ CYP2D6 Assay 50ml V8892
P450-Glo™ CYP2C19 Assay 50ml V8882
Pgp-Glo™ Assay System 10ml V3591
Pgp-Glo™ Assay System with P-glycoprotein 10ml V3601
MAO-Glo™ Assay 50ml V1402
Additional Sizes Available.
8. Summary of Changes
The following change was made to the 2/15 revision of this document:
1. The legal disclaimers were updated.
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1. Description
The CellTiter-Glo® Luminescent Cell Viability Assay(a–e) is a homogeneous method to determine the number of viable 
cells in culture based on quantitation of the ATP present, which signals the presence of metabolically active cells. The 
CellTiter-Glo® Assay is designed for use with multiwell-plate formats, making it ideal for automated high-throughput 
screening (HTS) and cell proliferation and cytotoxicity assays. The homogeneous assay procedure (Figure 1) involves 
adding a single reagent (CellTiter-Glo® Reagent) directly to cells cultured in serum-supplemented medium. Cell 
washing, removal of medium or multiple pipetting steps are not required.
The homogeneous “add-mix-measure” format results in cell lysis and generation of a luminescent signal proportional 
to the amount of ATP present (Figure 2). The amount of ATP is directly proportional to the number of cells present in 
culture in agreement with previous reports (1). The CellTiter-Glo® Assay relies on the properties of a proprietary 
thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), which generates a stable “glow-type” luminescent 
signal and improves performance across a wide range of assay conditions. The luciferase reaction for this assay is 
shown in Figure 3. The half-life of the luminescent signal resulting from this reaction is greater than fi ve hours 
(Figure 4). This extended half-life eliminates the need for reagent injectors and provides fl exibility for continuous or 
batch-mode processing of multiple plates. The unique homogeneous format reduces pipetting errors that may be 
introduced during the multiple steps required by other ATP-measurement methods.
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1. Description (continued)
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Figure 1. Flow diagram showing preparation and use of CellTiter-Glo® Reagent.
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System Advantages
• Homogeneous: “Add-mix-measure” format reduces the number of plate-handling steps to fewer than that 
required for similar ATP assays.
• Fast: Data can be recorded 10 minutes after adding reagent.
• Sensitive: Measures cells at numbers below the detection limits of standard colorimetric and fl uorometric assays.
• Flexible: Can be used with various multiwell formats. Data can be recorded by luminometer or CCD camera or 
imaging device.
• Robust: Luminescent signal is very stable, with a half-life >5 hours, depending on cell type and culture medium 
used.
• Able to Multiplex: Can be used with reporter gene assays or other cell-based assays from Promega (2,3).
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Figure 2. Cell number correlates with luminescent output. A direct relationship exists between luminescence 
measured with the CellTiter-Glo® Assay and the number of cells in culture over three orders of magnitude. Serial 
twofold dilutions of HEK293 cells were made in a 96-well plate in DMEM with 10% FBS, and assays were performed 
as described in Section 3.B. Luminescence was recorded 10 minutes after reagent addition using a GloMax®-Multi+ 
Detection System. Values represent the mean ± S.D. of four replicates for each cell number. The luminescent signal 
from 50 HEK293 cells is greater than three times the background signal from serum-supplemented medium without 
cells. There is a linear relationship (r2 = 0.99) between the luminescent signal and the number of cells from 0 to 50,000 
cells per well.
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1. Description (continued)
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Figure 3. The luciferase reaction. Mono-oxygenation of luciferin is catalyzed by luciferase in the presence of Mg2+, 
ATP and molecular oxygen.
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Figure 4. Extended luminescent half-life allows high-throughput batch processing. Signal stability is shown 
for three common cell lines. HepG2 and BHK-21 cells were grown and assayed in MEM containing 10% FBS, while 
CHO-K1 cells were grown and assayed in DME/F-12 containing 10% FBS. CHO-K1, BHK-21 and HepG2 cells, at 
25,000 cells per well, were added to a 96-well plate. After an equal volume of CellTiter-Glo® Reagent was added, plates 
were shaken and luminescence monitored over time with the plates held at 22°C. The half-lives of the luminescent 
signals for the CHO-K1, BHK-21 and HepG2 cells were approximately 5.4, 5.2 and 5.8 hours, respectively.
Promega CorporaƟ on · 2800 Woods Hollow Road · Madison, WI  53711-5399 USA · Toll Free in USA 800-356-9526 · 608-274-4330 · Fax 608-277-2516 5
www.promega.com  TB288 · Revised 12/12
2. Product Components and Storage Conditions
P R O D U C T  S I Z E  C AT. #
CellTiter-Glo® Luminescent Cell Viability Assay 10ml G7570
Substrate is suﬃ  cient for 100 assays at 100µl/assay in 96-well plates or 400 assays at 25µl/assay in 384-well 
plates. Includes:
• 1 × 10ml CellTiter-Glo® Buﬀ er
• 1 vial CellTiter-Glo® Substrate (lyophilized)
P R O D U C T  S I Z E  C AT. #
CellTiter-Glo® Luminescent Cell Viability Assay 10 × 10ml G7571
Each vial of substrate is suﬃ  cient for 100 assays at 100µl/assay in 96-well plates or 400 assays at 25µl/assay 
in 384-well plates (1,000 to 4,000 total assays). Includes:
• 10 × 10ml CellTiter-Glo® Buﬀ er
• 10 vials CellTiter-Glo® Substrate (lyophilized)
P R O D U C T  S I Z E  C AT. #
CellTiter-Glo® Luminescent Cell Viability Assay 100ml G7572
Substrate is suﬃ  cient for 1,000 assays at 100µl/assay in 96-well plates or 4,000 assays at 25µl/assay in 
384-well plates. Includes:
• 1 × 100ml CellTiter-Glo® Buﬀ er
• 1 vial CellTiter-Glo® Substrate (lyophilized)
P R O D U C T  S I Z E  C AT. #
CellTiter-Glo® Luminescent Cell Viability Assay 10 × 100ml G7573
Each vial of substrate is suﬃ  cient for 1,000 assays at 100µl/assay in 96-well plates or 4,000 assays at 
25µl/assay in 384-well plates (10,000 to 40,000 total assays). Includes:
• 10 × 100ml CellTiter-Glo® Buﬀ er
• 10 vials CellTiter-Glo® Substrate (lyophilized)
Storage Conditions: For long-term storage, store the lyophilized CellTiter-Glo® Substrate and CellTiter-Glo® Buﬀ er 
at –20°C. For frequent use, the CellTiter-Glo® Buﬀ er can be stored at 4°C or room temperature for 48 hours without 
loss of activity. See product label for expiration date information. Reconstituted CellTiter-Glo® Reagent (Buﬀ er plus 
Substrate) can be stored at room temperature for up to 8 hours with <10% loss of activity, at 4°C for 48 hours with 
~5% loss of activity, at 4°C for 4 days with ~20% loss of activity or at –20°C for 21 weeks with ~3% loss of activity. 
The reagent is stable for up to ten freeze-thaw cycles, with less than 10% loss of activity.
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3. Performing the CellTiter-Glo® Assay
Materials to Be Supplied by the User
• opaque-walled multiwell plates adequate for cell culture
• multichannel pipette or automated pipetting station for reagent delivery
• device (plate shaker) for mixing multiwell plates
• luminometer, CCD camera or imaging device capable of reading multiwell plates
• optional: ATP for use in generating a standard curve (Section 3.C)
3.A. Reagent Preparation
1. Thaw the CellTiter-Glo® Buﬀ er, and equilibrate to room temperature prior to use. For convenience the 
CellTiter-Glo® Buﬀ er may be thawed and stored at room temperature for up to 48 hours prior to use.
2. Equilibrate the lyophilized CellTiter-Glo® Substrate to room temperature prior to use.
3. Transfer the appropriate volume (10ml for Cat.# G7570 and G7571, or 100ml for Cat.# G7572 and G7573) of 
CellTiter-Glo® Buﬀ er into the amber bottle containing CellTiter-Glo® Substrate to reconstitute the lyophilized 
enzyme/substrate mixture. This forms the CellTiter-Glo® Reagent.
4. Mix by gently vortexing, swirling or inverting the contents to obtain a homogeneous solution. The CellTiter-Glo® 
Substrate should go into solution easily in less than 1 minute.
3.B. Protocol for the Cell Viability Assay
We recommend that you perform a titration of your particular cells to determine the optimal number and ensure that 
you are working within the linear range of the CellTiter-Glo® Assay. Figure 2 provides an example of such a titration of 
HEK293 cells using 0 to 50,000 cells per well in a 96-well format.
1. Prepare opaque-walled multiwell plates with mammalian cells in culture medium, 100µl per well for 96-well 
plates or 25µl per well for 384-well plates.
 Multiwell plates must be compatible with the luminometer used.
2. Prepare control wells containing medium without cells to obtain a value for background luminescence.
3. Add the test compound to experimental wells, and incubate according to culture protocol.
4. Equilibrate the plate and its contents at room temperature for approximately 30 minutes.
!
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5. Add a volume of CellTiter-Glo® Reagent equal to the volume of cell culture medium present in each well (e.g., 
add 100µl of reagent to 100µl of medium containing cells for a 96-well plate, or add 25µl of reagent to 25µl of 
medium containing cells for a 384-well plate).
6. Mix contents for 2 minutes on an orbital shaker to induce cell lysis.
7. Allow the plate to incubate at room temperature for 10 minutes to stabilize luminescent signal.
 Note: Uneven luminescent signal within standard plates can be caused by temperature gradients, uneven 
seeding of cells or edge eﬀ ects in multiwell plates.
8. Record luminescence.
 Note: Instrument settings depend on the manufacturer. An integration time of 0.25–1 second per well should 
serve as a guideline.
3.C. Protocol for Generating an ATP Standard Curve (optional)
It is a good practice to generate a standard curve using the same plate on which samples are assayed. We recommend 
ATP disodium salt (Cat.# P1132, Sigma Cat.# A7699 or GE Healthcare Cat.# 27-1006). The ATP standard curve 
should be generated immediately prior to adding the CellTiter-Glo® Reagent because endogenous ATPase enzymes 
found in sera may reduce ATP levels.
1. Prepare 1µM ATP in culture medium (100µl of 1µM ATP solution contains 10–10 moles ATP).
2. Prepare serial tenfold dilutions of ATP in culture medium (1µM to 10nM; 100µl contains 10–10 to 10–12 moles 
of ATP).
3. Prepare a multiwell plate with varying concentrations of ATP standard in 100µl medium 
(25µl for a 384-well plate).
4. Add a volume of CellTiter-Glo® Reagent equal to the volume of ATP standard present in each well.
5. Mix contents for 2 minutes on an orbital shaker.
6. Allow the plate to incubate at room temperature for 10 minutes to stabilize the luminescent signal.
7. Record luminescence.
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4. Appendix
4.A. Overview of the CellTiter-Glo® Assay
The assay system uses the properties of a proprietary thermostable luciferase to enable reaction conditions that 
generate a stable “glow-type” luminescent signal while simultaneously inhibiting endogenous enzymes released during 
cell lysis (e.g., ATPases). Release of ATPases will interfere with accurate ATP measurement. Historically, fi refl y 
luciferase purifi ed from Photinus pyralis (LucPpy) has been used in reagents for ATP assays (1,4–7). However, it 
has only moderate stability in vitro and is sensitive to its chemical environment, including factors such as pH and 
detergents, limiting its usefulness for developing a robust homogeneous ATP assay. Promega has successfully 
developed a stable form of luciferase based on the gene from another fi refl y, Photuris pennsylvanica (LucPpe2), using 
an approach to select characteristics that improve performance in ATP assays. The unique characteristics of this mutant 
(LucPpe2m) enabled design of a homogeneous single-reagent-addition approach to perform ATP assays with cultured 
cells. Properties of the CellTiter-Glo® Reagent overcome the problems caused by factors, such as ATPases, that 
interfere with ATP measurement in cell extracts. The reagent is physically robust and provides a sensitive and stable 
luminescent output.
Sensitivity and Linearity: The ATP-based detection of cells is more sensitive than other methods (8–10). In 
experiments performed by Promega scientists, the luminescent signal from 50 HEK293 cells is greater than three 
standard deviations above the background signal from serum-supplemented medium without cells. There is a linear 
relationship (r2 = 0.99) between the luminescent signal and the number of cells from 0 to 50,000 cells per well in the 
96-well format. The luminescence values in Figure 2 were recorded after 10 minutes of incubation at room temperature 
to stabilize the luminescent signal as described in Section 3.B. Incubation of the same 96-well plate used in the 
experiment shown in Figure 2 for 360 minutes at room temperature had little eﬀ ect on the relationship between 
luminescent signal and number of cells (r2 = 0.99).
Speed: The homogeneous procedure to measure ATP using the CellTiter-Glo® Assay is quicker than other ATP assay 
methods that require multiple steps to extract ATP and measure luminescence. The CellTiter-Glo® Assay also is faster 
than other commonly used methods to measure the number of viable cells (such as MTT, alamarBlue® or Calcein-AM) 
that require prolonged incubation steps to enable the cells’ metabolic machinery to convert indicator molecules into a 
detectable signal.
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4.B. Additional Considerations
Temperature: The intensity and decay rate of the luminescent signal from the CellTiter-Glo® Assay depends on the 
luciferase reaction rate. Environmental factors that aﬀ ect the luciferase reaction rate will change the intensity and 
stability of the luminescent signal. Temperature is one factor that aﬀ ects the rate of this enzymatic assay and thus the 
light output. For consistent results, equilibrate assay plates to a constant temperature before performing the assay. 
Transferring eukaryotic cells from 37°C to room temperature has little eﬀ ect on ATP content (5). We have demon-
strated that removing cultured cells from a 37°C incubator and allowing them to equilibrate to 22°C for 1–2 hours had 
little eﬀ ect on ATP content. For batch-mode processing of multiple assay plates, take precautions to ensure complete 
temperature equilibration. Plates removed from a 37°C incubator and placed in tall stacks at room temperature will 
require longer equilibration than plates arranged in a single layer. Insuﬃ  cient equilibration may result in a temperature 
gradient eﬀ ect between wells in the center and at the edge of the plates. The temperature gradient pattern also may 
depend on the position of the plate in the stack.
Chemicals: The chemical environment of the luciferase reaction aﬀ ects the enzymatic rate and thus luminescence 
intensity. Diﬀ erences in luminescence intensity have been observed using diﬀ erent types of culture media and sera. The 
presence of phenol red in culture medium should have little impact on luminescence output. Assaying 0.1µM ATP in 
RPMI medium without phenol red resulted in ~5% increase in luminescence output (in relative light units [RLU]) 
compared to assays in RPMI containing the standard concentration of phenol red, whereas assays in RPMI medium 
containing twice the normal concentration of phenol red showed a ~2% decrease in luminescence.
Solvents for the various test compounds may interfere with the luciferase reaction and thus the light output from the 
assay. Interference with the luciferase reaction can be detected by assaying a parallel set of control wells containing 
medium without cells. Dimethylsulfoxide (DMSO), commonly used as a vehicle to solubilize organic chemicals, has 
been tested at fi nal concentrations of up to 2% in the assay and only minimally aﬀ ects light output.
Plate Recommendations: We recommend using standard opaque-walled multiwell plates suitable for luminescence 
measurements. Opaque-walled plates with clear bottoms to allow microscopic visualization of cells also may be used; 
however, these plates will have diminished signal intensity and greater cross talk between wells. Opaque white tape 
may be used to decrease luminescence loss and cross talk.
Cellular ATP Content: Diﬀ erent cell types have diﬀ erent amounts of ATP, and values reported for the ATP level in 
cells vary considerably (1,4,11–13). Factors that aﬀ ect the ATP content of cells may aﬀ ect the relationship between cell 
number and luminescence. Anchorage-dependent cells that undergo contact inhibition at high densities may show a 
change in ATP content per cell at high densities, resulting in a nonlinear relationship between cell number and 
luminescence. Factors that aﬀ ect the cytoplasmic volume or physiology of cells also will aﬀ ect ATP content. For 
example, oxygen depletion is one factor known to cause a rapid decrease in ATP (1).
Mixing: Optimal assay performance is achieved when the CellTiter-Glo® Reagent is mixed completely with the 
cultured cells. Suspension cell lines (e.g., Jurkat cells) generally require less mixing to achieve lysis and extract ATP 
than adherent cells (e.g., L929 cells). Tests were done to evaluate the eﬀ ect of shaking the plate after adding the 
CellTiter-Glo® Reagent. Suspension cells cultured in multiwell plates showed only minor diﬀ erences in light output 
whether or not the plates were shaken after adding the CellTiter-Glo® Reagent. Adherent cells are more diﬃ  cult to lyse 
and show a substantial diﬀ erence between shaken and nonshaken plates.
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4.B. Additional Considerations (continued)
Several additional parameters related to reagent mixing include the force of delivery of CellTiter-Glo® Reagent, sample 
volume and dimensions of the well. All of these factors may aﬀ ect assay performance. The degree of reagent mixing 
required may be aﬀ ected by the method used to add the CellTiter-Glo® Reagent to the assay plates. Automated 
pipetting devices using a greater or lesser force of fl uid delivery may aﬀ ect the degree of subsequent mixing required. 
Complete reagent mixing in 96-well plates should be achieved using orbital plate shaking devices built into many 
luminometers and the recommended 2-minute shaking time. Special electromagnetic shaking devices that use a radius 
smaller than the well diameter may be required to eﬃ  ciently mix contents of 384-well plates. The depth of medium and 
geometry of the multiwell plates may have an eﬀ ect on mixing eﬃ  ciency. We recommend that you take these factors 
into consideration when performing the assay and empirically determine whether a mixing step is necessary for the 
individual application.
Luminometers
For highly sensitive luminometric assays, the luminometer model and settings greatly aﬀ ect the quality of data 
obtained. Luminometers from diﬀ erent manufacturers will vary in sensitivities and dynamic ranges. We recommend 
the GloMax® products because these instruments do not require gain adjustments to achieve optimal sensitivity and 
dynamic range. Additionally, GloMax® instruments are preloaded with Promega protocols for ease of use.
If you are not using a GloMax® luminometer, consult the operating manual for your luminometer to determine the 
optimal settings. The limits should be verifi ed on each instrument before analysis of experimental samples. The assay 
should be linear in some portion of the detection range of the instrument used. For an individual luminometer there 
may be diﬀ erent gain settings. We recommend that you optimize the gain settings.
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4.D. Related Products
Cell Proliferation Products
Product Size Cat.#
ApoLive-Glo™ Multiplex Assay 10ml G6410
ApoTox-Glo™ Triplex Assay 10ml G6320
CellTiter-Fluor™ Cell Viability Assay (fl uorescent) 10ml G6080
CellTiter-Blue® Cell Viability Assay (resazurin) 20ml G8080
CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS, colorimetric) 200 assays G3582
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (MTS, colorimetric) 1,000 assays G5421
CellTiter 96® AQueous MTS Reagent Powder 1g G1111
CellTiter 96® Non-Radioactive Cell Proliferation Assay (MTT, colorimetric) 1,000 assays G4000
Additional sizes available.
Cytotoxicity Assays
Product Size Cat.#
CytoTox-Glo™ Cytotoxicity Assay (luminescent)* 10ml G9290
Mitochondrial ToxGlo™ Assay* 10ml G8000
MultiTox-Glo Multiplex Cytotoxicity Assay (luminescent, fl uorescent)* 10ml G9270
MultiTox-Fluor Multiplex Cytotoxicity Assay (fl uorescent)* 10ml G9200
CytoTox-Fluor™ Cytotoxicity Assay (fl uorescent)* 10ml G9260
CytoTox-ONE™ Homogeneous Membrane Integrity Assay (LDH, fl uorometric)* 200–800 assays G7890
CytoTox-ONE™ Homogeneous Membrane Integrity Assay, HTP 1,000–4,000 assays G7892
CytoTox 96® Non-Radioactive Cytotoxicity Assay (LDH, colorimetric)* 1,000 assays G1780
GSH-Glo™ Glutathione Assay 10ml V6911
 50ml V6912
GSH/GSSG-Glo™ Assay 10ml V6611
 50ml V6612
*Additional sizes available.
Promega CorporaƟ on · 2800 Woods Hollow Road · Madison, WI  53711-5399 USA · Toll Free in USA 800-356-9526 · 608-274-4330 · Fax 608-277-2516 13
www.promega.com  TB288 · Revised 12/12
Luminometers
Product Size Cat.#
GloMax®-Multi+ Detection System with Instinct™ Software: 
Base Instrument with Shaking 1 each E8032
GloMax®-Multi+ Detection System with Instinct™ Software: 
Base Instrument with Heating and Shaking 1 each E9032
GloMax®-Multi+ Luminescence Module 1 each E8041
Apoptosis Products
Product Size Cat.#
Caspase-Glo® 2 Assay* 10ml G0940
Caspase-Glo® 6 Assay* 10ml G0970
Caspase-Glo® 3/7 Assay* 2.5ml G8090
Caspase-Glo® 8 Assay* 2.5ml G8200
Caspase-Glo® 9 Assay* 2.5ml G8210
Apo-ONE® Homogeneous Caspase-3/7 Assay 1ml G7792
DeadEnd™ Fluorometric TUNEL System 60 reactions G3250
DeadEnd™ Colorimetric TUNEL System 20 reactions G7360
Anti-ACTIVE® Caspase-3 pAb 50µl G7481
Anti-PARP p85 Fragment pAb 50µl G7341
Anti-pS473 Akt pAb 40µl G7441
Caspase Inhibitor Z-VAD-FMK, 20mM 50µl G7231
 125µl G7232
*Additional sizes available.
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